Compare Quest Diagnostics Inc (DGX) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MBS ETF — how do they compare? Quest Diagnostics Inc trades at $237.54 (market cap $26.21B), while iShares MBS ETF trades at $93.23. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while iShares MBS ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| DGX | MBB | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | — |
52-Week High | $238.50 | $96.91 |
52-Week Low | $173.49 | $92.72 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
MBB trades at $93.28, up 0.38% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent corporate actions include dividend payments of $0.33-$0.34 per share in mid-2026. Focus Financial Network increased its stake by 13.8% in the latest quarter, holding 49,056 shares as of its most recent SEC filing.
The outlook remains cautious due to bearish technical indicators and limited fundamental data availability. Key risks include market volatility and reliance on institutional interest. Investment opportunities hinge on dividend income and potential institutional accumulation, but the lack of current financial metrics warrants careful evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
